Most of the retatrutide conversation is still stuck on one number: the ~28.3% average body weight loss reported at 12mg over 80 weeks in TRIUMPH-1. But if you want to understand why Eli Lilly built a triple agonist instead of stopping at two receptors, the more interesting story is happening in the liver. That is also where the retatrutide vs tirzepatide comparison stops being a scoreboard argument and starts being a mechanism argument.

Quick note on scope and honesty: this piece is about mechanism and published trial science, not a breaking-news scoop. Where the evidence is early-phase, small or unreplicated, we say so.

Retatrutide vs tirzepatide: what the third receptor is actually for

The three drugs people compare are not variations on a theme:

  • Semaglutide (Ozempic, Wegovy) — one receptor: GLP-1.
  • Tirzepatide (Mounjaro, Zepbound) — two receptors: GLP-1 + GIP.
  • Retatrutide — three receptors: GLP-1 + GIP + glucagon.

GLP-1 and GIP largely work on the demand side of the equation: appetite, satiety, gastric emptying, insulin response. The glucagon arm is different in kind. Glucagon receptor agonism is a supply-side lever — it acts directly on the liver and on energy expenditure rather than only on how much you feel like eating.

That is the single biggest conceptual difference in retatrutide vs tirzepatide. Tirzepatide gets you to eat less, very effectively. Retatrutide is designed to do that and push the liver to burn stored fat, which is why weight loss curves in the retatrutide programme have looked steeper — and why the liver readouts have drawn as much specialist attention as the scales. More on how the molecule is built in what is retatrutide.

The liver-fat signal: what the phase 2a data showed

Retatrutide has been studied specifically in metabolic dysfunction-associated steatotic liver disease (MASLD — the condition formerly called NAFLD), in a randomised phase 2a sub-study published in Nature Medicine. In adults with obesity and fatty liver, higher retatrutide doses produced very large relative reductions in liver fat at 24 weeks — on the order of 80%+ from baseline at the top doses — with the large majority of participants dropping below the threshold that defines steatosis at all.

Three caveats matter, and they matter a lot:

  1. This was phase 2a. Small numbers, exploratory endpoints, and a sub-study population — not a confirmatory phase 3 liver trial.
  2. The endpoint was imaging, not biopsy. Liver fat measured by MRI-PDFF is a legitimate and sensitive marker, but it is not the same as proving improvement in inflammation or fibrosis, which is what regulators want for a MASH indication.
  3. Weight loss itself reduces liver fat. Untangling how much of the effect is the glucagon arm doing distinct work versus how much simply follows from losing a lot of weight requires dedicated trials.

So: a genuinely striking early signal, not a proven liver drug. Anyone telling you retatrutide "treats fatty liver disease" is ahead of the evidence.

Why the liver angle changes the commercial picture

If the liver effect holds up in larger, longer, biopsy-anchored studies, retatrutide stops being only an obesity drug and becomes a metabolic-disease drug with multiple potential indications. That has three practical consequences worth understanding:

  • More trials, more time. Extra indications mean extra programmes, and each one adds review complexity rather than speed.
  • A different reimbursement conversation. Payers fund liver and cardiometabolic disease more readily than they fund weight loss alone. Australia's reimbursement system behaves the same way, which is directly relevant given roughly 66.8% of Australian adults are overweight or obese and fatty liver travels with that population. A drug that documents organ-level benefit has a stronger case in front of a reimbursement committee than one that documents kilograms.
  • Safety scrutiny scales with ambition. Glucagon agonism is the newest of the three arms, and it is the one that brings dose-dependent heart-rate increases and glucose-handling questions into the frame. We cover that in safety.

What this does not change

Retatrutide remains investigational. It is not TGA-approved in Australia, not approved anywhere else, and Eli Lilly has signalled regulatory filings from 2027. Phase 2a liver data does not shorten that timeline, and no early signal in a sub-study substitutes for the full TRIUMPH programme reading out. The current trial landscape is tracked in clinical trials, and the Australian access picture in Australia.

Want the next readout — liver, cardiometabolic or headline weight — explained without the hype? Join the free updates list.

FAQ

Is retatrutide better than tirzepatide?

There is no completed head-to-head trial of retatrutide against tirzepatide, so nobody can answer this definitively. Cross-trial comparisons suggest larger average weight loss with retatrutide, but different trials, populations and durations make those comparisons unreliable.

Does retatrutide help fatty liver disease?

A phase 2a randomised sub-study published in Nature Medicine reported large reductions in liver fat on MRI imaging at higher doses over 24 weeks. That is an encouraging early signal, not proof of benefit for liver inflammation or fibrosis, and it has not yet been confirmed in phase 3.

What does the glucagon receptor add to retatrutide?

Glucagon receptor agonism acts on the liver and on energy expenditure, rather than only suppressing appetite the way GLP-1 and GIP largely do. It is the main mechanistic difference between retatrutide and two-receptor drugs like tirzepatide.

When will retatrutide be approved?

Eli Lilly has indicated it plans to begin regulatory filings from 2027, with approvals following after review. It is currently investigational everywhere, including in Australia, where it has no TGA approval.

Sources

Disclaimer: This article is general information only and is not medical advice. Retatrutide is an investigational medicine and is not approved by the TGA or any other regulator. Do not start, stop or change any treatment without advice from a qualified health professional. retatrutide.net.au is an independent information site and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.